Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENGRAF vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants,Treatment of active rheumatoid arthritis (FDA-approved for moderate to severe),Treatment of psoriasis (FDA-approved for severe, recalcitrant cases),Off-label: nephrotic syndrome, aplastic anemia, ulcerative colitis, atopic dermatitis
Management of mild to moderate pain,Reduction of fever
5-15 mg/kg/day orally in divided doses every 12 hours.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal half-life is approximately 8.4 hours (range 5-18 hours) in adult volunteers; prolonged in hepatic impairment.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Hepatic metabolism primarily via CYP3A4 enzyme; also substrate for CYP3A5. Metabolized to multiple metabolites with variable activity, including AM1 (hydroxylated), AM9 (N-demethylated), and AM4N (cyclized). Undergoes extensive first-pass metabolism.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily biliary/fecal (94%); renal excretion accounts for 6% (0.1% unchanged).
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
90-98% bound to plasma proteins, primarily lipoproteins, albumin, and alpha-1-acid glycoprotein.
10-25% bound to albumin at therapeutic concentrations.
3.5 L/kg (range 1.2-4.8 L/kg) in renal transplant recipients; distribution is extensive and variable.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral bioavailability is 30% (range 10-60%), variable due to first-pass metabolism and food effects.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
GFR <30 m L/min: reduce dose by 50%.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
4-10 mg/kg/day orally in divided doses every 12 hours; adjusted to target trough levels.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at lower end of dosing range and titrate based on renal function and drug levels.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Increased susceptibility to infection and development of lymphoma and other malignancies, particularly of the skin. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe cyclosporine.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Nephrotoxicity: Monitor renal function regularly; risk increased with high doses, other nephrotoxic drugs, or prolonged use.,Hepatotoxicity: Monitor liver function.,Hypertension: Common; require blood pressure control.,Neurotoxicity: Including tremor, convulsions, headache, and paresthesias.,Hyperkalemia: Monitor serum potassium, especially with potassium-sparing diuretics or ACE inhibitors.,Hypomagnesemia: Supplementation may be required.,Increased risk of infections and lymphoproliferative disorders.,Potential for anaphylactic reactions with IV formulation (due to Cremophor EL).,Carcinogenesis: Especially skin malignancies; minimize UV exposure.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to cyclosporine or any component of the formulation (including Cremophor EL for IV),Uncontrolled hypertension,Malignancy (except non-melanoma skin cancer) in patients with rheumatoid arthritis or psoriasis,Concomitant use with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, or coal tar (for psoriasis patients),Abnormal renal function with uncontrolled hypertension (for psoriasis patients),Pregnancy (category C; additional risk of premature birth and low birth weight)
Hypersensitivity to acetaminophen or any component of the formulation
Grapefruit and grapefruit juice increase cyclosporine levels and must be avoided. High-potassium foods (e.g., bananas, oranges, potatoes) may increase hyperkalemia risk; monitor intake. Avoid St. John's wort as it reduces drug levels.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction, prematurity, and low birth weight. Consider risk-benefit; avoid if possible, but may be used if essential.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Cyclosporine is excreted into breast milk. Milk-to-plasma ratio approximately 0.3-0.6. Potential for infant immunosuppression and growth inhibition. Weigh benefits against risks; monitor infant for adverse effects.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Pregnancy reduces cyclosporine oral bioavailability and increases clearance; dose may need to be increased by 20-50% to maintain therapeutic trough levels. Frequent level monitoring recommended, especially in third trimester. Postpartum dose reduction likely needed.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Monitor trough levels (target 100-400 ng/m L) and renal function closely. Calcineurin inhibitors cause nephrotoxicity; dose reduction may be necessary. Avoid use with potassium-sparing diuretics or ACE inhibitors due to hyperkalemia risk. Grapefruit increases levels; avoid coadministration. Remember to adjust dose for hepatic impairment.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take with or without food consistently at the same times each day.,Do not consume grapefruit or grapefruit juice while on this medication.,Report signs of infection, tremors, or changes in urine output immediately.,Avoid live vaccinations and limit sun exposure due to increased skin cancer risk.,Do not stop or change dose without consulting your doctor.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENGRAF vs INJECTAPAP, answered by our medical review team.
GENGRAF is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor; binds to cyclophilin, inhibits calcineurin-dependent T-cell activation, preventing nuclear factor of activated T-cells (NF-AT) dephosphorylation and translocation, thereby reducing IL-2 and other cytokine gene transcription.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENGRAF and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENGRAF is: 5-15 mg/kg/day orally in divided doses every 12 hours.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENGRAF and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENGRAF is classified as Category C. First trimester: Cyclosporine crosses the placenta. Limited human data, but no major malformations attributed. Second and third trimesters: Risk of intrauterine growth restriction,. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.